Skip to content
2000
  1. Home
  2. A-Z Publications
  3. New Emirates Medical Journal
  4. Fast Track Articles
  5. Fast Track Article
image of Risk Stratification in Pulmonary Hypertension in the UAE
file format pdf download PDF

Abstract

Risk stratification in pulmonary arterial hypertension is critical in determining therapeutic strategies for patients. Patients are stratified into low-, intermediate-, and high-risk groups based on determinants of prognosis like clinical assessment, exercise tests, biochemical markers, echocardiography, and haemodynamic tests. The primary objective of treatment is to shift each of the component tests into a low-risk zone either by treatment escalation alone, as in the case of intermediate-risk patients, or by a combination of treatment escalation and repeat evaluation by right heart catheterisation in high-risk patients. Low-risk patients should be clinically assessed at least every 3 months, but follow-up is more frequent for intermediate- and high-risk patients. Apart from improving survival rates, health-related quality of life is also assessed at baseline and follow-up visits, which may predict the prognosis. Additionally, therapeutic drug monitoring is also essential during visits due to the risk of major side effects during treatment initiation or dose escalation. Initial and follow-up risk stratification can prevent delays in the intensification of therapy, but insurance denials act as a barrier to this approach. Therefore, a dedicated insurance team is required for approval of testing and therapies and a fast-track process to communicate with the pulmonary hypertension expert centre. It can be concluded that risk stratification improves the treatment approach and helps make individualised treatment decisions. It also helps healthcare professionals better allocate treatment resources in cases of scarcity.

© 2024 The Author(s). Published by Bentham Science.
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Loading

Article metrics loading...

/content/journals/nemj/10.2174/0102506882333499241114120006
2024-12-16
2025-04-07

  • From This Site

    /content/journals/nemj/10.2174/0102506882333499241114120006
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
The full text of this item is not currently available.

References

  1. Humbert M Kovacs G Hoeper MM Badagliacca R Berger RMF Brida M ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2023 61 1 2200879
    [Google Scholar]
  2. Zelniker T. Uhlmann L. Spaich S. Friedrich J. Preusch M.R. Meyer F.J. Katus H.A. Giannitsis E. Novel biomarkers for risk stratification in pulmonary arterial hypertension. ERJ Open Res. 2015 1 2 00008-2015 10.1183/23120541.00008‑2015 27730146
    [Google Scholar]
  3. Galiè N. Channick R.N. Frantz R.P. Grünig E. Jing Z.C. Moiseeva O. Preston I.R. Pulido T. Safdar Z. Tamura Y. McLaughlin V.V. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur. Respir. J. 2019 53 1 1801889 10.1183/13993003.01889‑2018 30545971
    [Google Scholar]
  4. van de Veerdonk M.C. Kind T. Marcus J.T. Mauritz G.J. Heymans M.W. Bogaard H.J. Boonstra A. Marques K.M.J. Westerhof N. Vonk-Noordegraaf A. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. J. Am. Coll. Cardiol. 2011 58 24 2511 2519 10.1016/j.jacc.2011.06.068 22133851
    [Google Scholar]
  5. van Wolferen S.A. Marcus J.T. Boonstra A. Marques K.M.J. Bronzwaer J.G.F. Spreeuwenberg M.D. Postmus P.E. Vonk-Noordegraaf A. Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. Eur. Heart J. 2007 28 10 1250 1257 10.1093/eurheartj/ehl477 17242010
    [Google Scholar]
  6. van de Veerdonk M.C. Marcus J.T. Westerhof N. de Man F.S. Boonstra A. Heymans M.W. Bogaard H.J. Vonk Noordegraaf A. Signs of right ventricular deterioration in clinically stable patients with pulmonary arterial hypertension. Chest 2015 147 4 1063 1071 10.1378/chest.14‑0701 25376008
    [Google Scholar]
  7. Swift A.J. Rajaram S. Campbell M.J. Hurdman J. Thomas S. Capener D. Elliot C. Condliffe R. Wild J.M. Kiely D.G. Prognostic value of cardiovascular magnetic resonance imaging measurements corrected for age and sex in idiopathic pulmonary arterial hypertension. Circ. Cardiovasc. Imaging 2014 7 1 100 106 10.1161/CIRCIMAGING.113.000338 24275955
    [Google Scholar]
  8. Humbert M. Lau E.M.T. Risk stratification in pulmonary arterial hypertension: Do not forget the patient perspective. Am. J. Respir. Crit. Care Med. 2021 203 6 675 677 10.1164/rccm.202012‑4350ED 33357026
    [Google Scholar]
  9. Weatherald J. Boucly A. Sitbon O. Risk stratification in pulmonary arterial hypertension. Curr. Opin. Pulm. Med. 2018 24 5 407 415 10.1097/MCP.0000000000000510 30004992
    [Google Scholar]
  10. Hoeper M.M. Pletz M.W. Golpon H. Welte T. Prognostic value of blood gas analyses in patients with idiopathic pulmonary arterial hypertension. Eur. Respir. J. 2007 29 5 944 950 10.1183/09031936.00134506 17301100
    [Google Scholar]
  11. Min J. Badesch D. Chakinala M. Elwing J. Frantz R. Horn E. Klinger J. Lammi M. Mazimba S. Sager J. Shlobin O. Simon M. Thenappan T. Grinnan D. Ventetuolo C. Al-Naamani N. Raval A. Raina A. Hemnes A. Burger C. Dunbar Ivy D. Yung D. Zwicke D. Berman-Rosenzweig E. Ramani G. Farr G. James Ford H. Runo J. Fineman J. Feldman J. Swisher J. Ryan J. Wesley McConnell J. Presberg K. Parikh K. Cadaret L. Avdalovic M. Duncan M. Eggert M. Varghese N. Boyce P. Leary P. Foley R. James White R. Frantz R. Zamanian R. Hirsch R. Bakshi S. Bartolome S. Kawut S. Mathai S. De Marco T. Williamson T. Bull T. PHAR Investigators Prediction of health-related quality of life and hospitalization in pulmonary arterial hypertension: The pulmonary hypertension association registry. Am. J. Respir. Crit. Care Med. 2021 203 6 761 764 10.1164/rccm.202010‑3967LE 33211974
    [Google Scholar]
  12. Boucly A. Weatherald J. Savale L. Jaïs X. Cottin V. Prevot G. Picard F. de Groote P. Jevnikar M. Bergot E. Chaouat A. Chabanne C. Bourdin A. Parent F. Montani D. Simonneau G. Humbert M. Sitbon O. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur. Respir. J. 2017 50 2 1700889 10.1183/13993003.00889‑2017 28775050
    [Google Scholar]
  13. Zelniker T.A. Huscher D. Vonk-Noordegraaf A. Ewert R. Lange T.J. Klose H. Dumitrescu D. Halank M. Held M. Gall H. Pittrow D. Hoeper M.M. Frankenstein L. The 6MWT as a prognostic tool in pulmonary arterial hypertension: Results from the COMPERA registry. Clin. Res. Cardiol. 2018 107 6 460 470 10.1007/s00392‑018‑1207‑5 29368137
    [Google Scholar]
  14. Sitbon O. Benza R.L. Badesch D.B. Barst R.J. Elliott C.G. Gressin V. Lemarié J.C. Miller D.P. Muros-Le Rouzic E. Simonneau G. Frost A.E. Farber H.W. Humbert M. McGoon M.D. Validation of two predictive models for survival in pulmonary arterial hypertension. Eur. Respir. J. 2015 46 1 152 164 10.1183/09031936.00004414 25837032
    [Google Scholar]
  15. Galiè N. Humbert M. Vachiery J.L. Gibbs S. Lang I. Torbicki A. Simonneau G. Peacock A. Vonk Noordegraaf A. Beghetti M. Ghofrani A. Gomez Sanchez M.A. Hansmann G. Klepetko W. Lancellotti P. Matucci M. McDonagh T. Pierard L.A. Trindade P.T. Zompatori M. Hoeper M. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Respir. J. 2015 46 4 903 975 10.1183/13993003.01032‑2015 26318161
    [Google Scholar]
  16. Galiè N. Humbert M. Vachiery J.L. Gibbs S. Lang I. Torbicki A. Simonneau G. Peacock A. Vonk Noordegraaf A. Beghetti M. Ghofrani A. Gomez Sanchez M.A. Hansmann G. Klepetko W. Lancellotti P. Matucci M. McDonagh T. Pierard L.A. Trindade P.T. Zompatori M. Hoeper M. ESC Scientific Document Group ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Heart J. 2016 37 1 67 119 10.1093/eurheartj/ehv317 26320113
    [Google Scholar]
  17. Diamanti E. Karava V. Yerly P. Aubert J.D. Carbon monoxide diffusion capacity as a severity marker in pulmonary hypertension. J. Clin. Med. 2021 11 1 132 10.3390/jcm11010132 35011871
    [Google Scholar]
  18. Benza R.L. Kanwar M.K. Raina A. Scott J.V. Zhao C.L. Selej M. Elliott C.G. Farber H.W. Development and Validation of an abridged version of the reveal 2.0 risk score calculator, reveal lite 2, for use in patients with pulmonary arterial hypertension. Chest 2021 159 1 337 346 10.1016/j.chest.2020.08.2069 32882243
    [Google Scholar]
  19. Frantz RP SO Raina A Wu B Broderick M Change in reveal lite 2 and COMPERA 2.0 risk status in patients with pulmonary arterial hypertension initiating oral treprostinil on dual background therapy: A retrospective chart review. Eur. Heart J. 2022 43 2 544.1919
    [Google Scholar]
  20. Boucly A. Weatherald J. Savale L. de Groote P. Cottin V. Prévot G. Chaouat A. Picard F. Horeau-Langlard D. Bourdin A. Jutant E.M. Beurnier A. Jevnikar M. Jaïs X. Simonneau G. Montani D. Sitbon O. Humbert M. External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry. Eur. Respir. J. 2022 59 6 2102419 10.1183/13993003.02419‑2021 34737227
    [Google Scholar]
/content/journals/nemj/10.2174/0102506882333499241114120006
Loading
Risk Stratification in Pulmonary Hypertension in the UAE
Bentham Science Publishers , e02506882333499; https://doi.org/10.2174/0102506882333499241114120006
/content/journals/nemj/10.2174/0102506882333499241114120006
/content/journals/nemj/10.2174/0102506882333499241114120006
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: Pulmonary arterial hypertension ; Biochemical markers ; Exercise capacity ; Treatment response ; Right ventricular function ; Risk stratification

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test